Phosphodiesterase 5 inhibitors in male sexual dysfunction

Current Opinion in Urology

Volumn 13, Issue 5, 2003, Pages 405-410

  Kuthe, Andrea ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Erectile dysfunction; Phosphodiesterase 5 inhibitor; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE CIPIONATE; VARDENAFIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DYSPEPSIA; ENTERITIS; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; MALE; MALE SEXUAL DYSFUNCTION; MIGRAINE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECTUM CARCINOMA; RECTUM RESECTION; REVIEW; SIDE EFFECT; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CARBOLINES; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; SULFONES; TRIAZINES;

EID: 0042261505     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200309000-00008     Document Type: Review

References (48)

1. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11:150-155.
2. Burns F, Zhao AZ, Beavo JA. Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiological implications. Adv Pharmacol 1996; 36:29-48.
3. Dousa TP. Cyclic-3′,5′-nucleotide phosphodiesterase isoenzymes in cell biology and pathophysiology of the kidney. Kidney Int 1999; 55:29-62.
4. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75:725-748.
5. Bolger G, Michaeli T, Martins T, et al. A family of human phosphodiesterase homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 1993; 13:6558-6571.
6. Manganiello VC, Murata T, Taira M, et al. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 1995; 322:1-13.
7. Katzenstein L. Viagra: the remakable story of the discovery and launch. New York: CMD Publishing; 2001.
8. Kuthe A, Magert HJ, Uckert S, et al. Gene expression of the phosphodiesterase 3A and 5A in human corpus cavernosum. Eur Urol 2000; 38;108-114.
9. Goldstein I, Lue TF, Padma-Nathan H. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338:1397-1404.
10. Derry F, Hultling C, Seftel AD, Sipski ML. Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology 2002; 60 (2 Suppl 2):49-57.
11. Sanchez Ramos A, Vidal J, Jauregui ML. Efficacy, safety and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord 2001; 39:637-643.
12. Seidman SN, Roose SP, Menza MA. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001; 158:1623-1630.
13. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001; 44:1296-1301.
14. Incrocci L, Koper PC, Hop WC, Slob AK. Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 2001; 51:1190-1195.
15. Perimenis P, Markou S, Gyftopoulos K, et al. Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction: discerning study on sildenafil and diabetes. Eur Urol 2002; 41:387-391. This is a very interesting trial. It shows critically that self-injection therapy with vasoactive drugs is preferred by many diabetic patients depending on the type of diabetes, the kind of the injected drug and age.
16. Stuckey BG, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003; 26:279-284.
17. Nurnberg HG, Seidman SN, Gelenberg AJ, et al. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology 2002; 60 (2 Suppl. 2):58-66. This is an excellent review that compares four clinical trials concerning men with depression and ED.
18. Lindsey I, George B, Kettlewell M, Mortensen N. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis Colon Rectum 2002; 45:727-732.
19. Barrou B, Cuzin B, Malavaud B, et al. Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol Dial Transplant 2003; 18:411-417.
20. Chatterjee R, Kottaridis PD, McGarrigle HH, Linch DC. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant 2002; 29:607-610.
21. Seibel I, Poli De Figueiredo CE, Teloken C, Moraes JF. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol 2002; 13:2770-2775.
22. YenicerioGlu Y, Kefi A, Asian G, et al. Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis. BJU Int 2002; 90:442-445.
23. Derry F, Hultling C, Seftel AD, Sipski ML. Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology 2002; 60 (2 Suppl 2):49-57.
24. Fink HA, MacDonald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch intern Med 2002; 162:1349-1360.
25. McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60 (2 Suppl 2):28-38. This paper contains 'recommendations for sildenafil treatment optimization' for physicians.
26. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126:241-247. This publication shows that sildenafil can induce migraine and tries to explain the mechanism of this phenomenon.
27. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159:2164-2171.
28. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction; the first at-home clinical trial. Int J Impot Res 2001; 13:192-199.
29. Young JM. Vardenafil. Expert Opin Investig Drugs 2002; 11:1487-1496. An enclosing review describing the development of vardenafil from in-vitro assays to phase III trials with both broad and special populations.
30. Sommer F, Engelmann U. Vardenafil Bayer Yakuhin. Curr Opin Investig Drugs 2002; 3:607-613.
31. Ormrod D, Easthope SE, Figgitt DP. Vardenafil. Drugs Aging 2002; 19:217-227. A review about the pharmacodynamic properties and profile, clinical trials, tolerability, dosage and administration of vardenafil; helpful for physicians.
32. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Cell Cardiol 2002; 40:2006-2012. The authors concluded that vardenafil does not impair the ability of patients with stable coronary artery disease to exercise at equivalent or greater levels than those required for sexual intercourse.
33. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26:777-783.
34. Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002; 56:300-304. An excellent review on tadalafil, including the kinetic profile, clinical trial data and a comparison with sildenafil.
35. Padma-Nathan H, McMurray JG, Pullman WE, et al. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13:2-9.
36. Kuan J, Brock G. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2002; 11:1605-1613. A review focussing on phase II and III trials for tadalafil in men with ED of various causes.
37. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 (Suppl 1):57-64.
38. Brock GB. Tadalafil: a new agent for erectile dysfunction. Can J Urol 2003; 10:17-22. A review of clinical trials with tadalafil, which gives a good overview of its efficacy and safety.
39. Patterson B, Bedding A, Jewell H, et al. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 2001; 13 (Suppl 4):A120.
40. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168:1332-1336. A large clinical trail investigating the efficacy of tadalafil in men with different aetiologies (including hypertension, coronary artery diseases, diabetes and depression) and ED.
41. Saenz De Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25:2159-2164. This phase III study on tadalafil demonstrates its efficacy and good tolerance in diabetic men with ED.
42. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56:453-459. This is a good review on the pharmacological profile of phosphodiesterase 5 inhibitors in comparison.
43. Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol 2003; 10:12-16.
44. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur J Med Res 2002; 7:435-446.
45. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002; 14:466-471. A review on the three phosphodiesterase 5 inhibitors in men with diabetes and ED; every drug is compared with the general population (non-diabetic individuals) and against each other.
46. Prickaerts J, van Staveren WC, Sik A, et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 2002; 113:351-361. This is an interesting study comparing sildenafil and vardenafil on recogition memory and on the hippocampal cGMP signal cascade in rats and mice.
47. Sarfati M, Mateo V, Baudet S, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003; 101:265-269. This excellent paper indicates that the phosphodiesterase 5 inhibitors, sildenafil and vardenafil, have the potential to induce apoptosis of B-chronic lymphocytic leukaemia cells.
48. Jain NK, Patil CS, Singh A, Kulkarni SK. Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology 2003; 67:150-156. This is an interesting study on the interaction between phosphodiesterase 5 inhibitors and morphine. This drug combination might possibly be used in future for the management of inflammatory conditions after tissue injury.